KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC

Ren, SX; Feng, JF; Ma, SL; Chen, HJ; Ma, ZY; Huang, C; Zhang, L; He, JX; Wang, CL; Zhou, JY; Danchaivijtr, P; Wang, CC; Vynnychenko, I; Wang, K; Orlandi, F; Sriuranpong, V; Li, B; Ge, J; Dang, T; Zhou, CC

Zhou, CC (通讯作者)，Tongji Univ, Shanghai Pulm Hosp, Sch Med, 507 Zhengmin Rd, Shanghai 200443, Peoples R China.

INTERNATIONAL JOURNAL OF CANCER, 2023; 153 (3): 623

Abstract

KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that compared pembrolizumab vs docetaxel in previously treated, programmed dea......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索